Aurinia Pharmaceuticals Inc. provided revenue guidance for the fiscal year 2024. for the year, the company expects net product revenue guidance of $200 million- $220 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.46 USD | +3.61% | +5.81% | -39.27% |
Jun. 05 | Aurinia Pharmaceuticals Inc. Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis | CI |
Jun. 03 | Lucien Selce Sends Letter to Aurinia shareholders | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.27% | 779M | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+4.54% | 22.67B | |
-9.61% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Fiscal Year 2024